Carbamazepine versus phenytoin monotherapy for epilepsy: An individual participant data review

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 7, 2019, Pages

  Nevitt, Sarah J ^a   Marson, Anthony G ^a   Smith, Catrin Tudur ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PHENYTOIN; ANTICONVULSIVE AGENT;

ANTICONVULSANT THERAPY; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT OUTCOME; CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; TREATMENT FAILURE;

ANTICONVULSANTS; CARBAMAZEPINE; CHILD; EPILEPSY; HUMANS; PHENYTOIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEIZURES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 85070848533     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001911.pub4     Document Type: Review

References (103)

1. Callaghan 1985 Callaghan N, Kenny RA, O’Neill B, Crowley M, Goggin T. A comparative study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. British Journal of Clinical Practice 1983;27:7–9.
2. Callaghan N, Kenny RA, O’Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 1985;48 (7):639–44.
3. Goggin T, Casey C, Callaghan N. Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy. Irish Medical Journal 1986;79(6):150–6.
4. Czapinski 1997 Czapinski P, Terczynski A, Czapinska E. Randomised 36-month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with focal complex seizures. Epilepsia 1997;38 Suppl(3):42.
5. De Silva 1996 De Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347(9003):709–13.
6. Forsythe 1991 Berg I, Butler A, Ellis M, Foster J. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Developmental Medicine and Child Neurology 1993;35(2): 149–57.
7. Forsythe I, Butler R, Berg I, McGuire R. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology 1991;33(6): 524–34.
8. Heller 1995 Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry 1995;58(1):44–50.
9. Mattson 1985 Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in focal and secondary generalized tonic-clonic seizures. New England Journal of Medicine 1985;313(3):145–51.
10. Miura 1993 Miura H. Developmental and therapeutic pharmacology of antiepileptic drugs. Japanese Journal of Psychiatry and Neurology 1993;47(2):169–74.
11. Ogunrin 2005 Ogunrin O, Adamolekun B, Ogunniyi A. Cognitive effects of anti-epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences 2005;24:18–24.
12. Pulliainen 1994 Pulliainen V, Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-up. Epilepsia 1995;36(12): 1195–202.
13. Pulliainen V, Jokelainen M. Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients. Acta Neurologica Scandinavica 1994;89 (2):81–6.
14. Ramsay 1983 Berger JR, Ramsay RE, Wilder BJ, Bruni J. A double-blind study comparing carbamazepine to phenytoin as initial seizure therapy. Neurology 1981;31(4 Pt 2):159.
15. ∗ Ramsay RE, Wilder BJ, Berger JR, Bruni J. A double blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983;33(7):904–10.
16. Ravi Sudhir 1995 Ravi Sudhir RV, Sawhney IM, Prabhakar S, Pershad D, Nain CK. Comparative cognitive effects of phenytoin and carbamazepine in adult epileptics. Neurology India 1995;43 (4):186–92.
17. Bird 1966 Bird CA, Griffin BP, Miklaszewska JM, Galbraith AW. Tegretol (carbamazepine): a controlled trial of new anticonvulsant. British Journal of Psychiatry 1966;112:737–42.
18. Bittencourt 1993 Bittencourt PR, Antoniuk SA, Bigarella MM, Da Costa JC, Doro MP, Ferreira AS, et al. Carbamazepine and phenytoin in epilepsies refractory to barbiturates: efficacy, toxicity and mental function. Epilepsy Research 1993;16(2):147–55.
19. Canadian Study 1998 Bawden HN, Camfield CS, Camfield PR, Cunningham C, Darwish H, Dooley JM, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Research 1999;33(2-3):133–43.
20. Canadian Study Group for Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 1998;39(9): 952–9.
21. Cereghino JJ, Brock JT, White BG, Penry JK. Evaluation of carbamazepine in epileptic patients. Neurology 1973;23(4): 433.
22. ∗ Cereghino JJ, Brock JJ, Van Meter JC, Penry JK, Smith LD, White BG. Carbamazepine for epilepsy. A controlled prospective evaluation. Neurology 1974;24(5):401–10.
23. Hakami 2012 Hakami T, Todaro M, Petrovski S, MacGregor L, Velakoulis D, Tan M, et al. Substitution monotherapy with levetiracetam vs older antiepileptic drugs: A randomized comparative trial. Archives of Neurology 2012;69(12): 1563–71.
24. ∗ Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy and Behaviour 2003;4(6):659–66.
25. Martinez W, Kaminow L, Nanry KP, Hammer AE, Barrett PS. Evaluation of lamotrigine versus carbamazepine, phenytoin, or divalproex sodium as monotherapy for epilepsy patients who failed or could not tolerate previous antiepileptic drug therapy. Epilepsia 2000;41(Suppl 7):100.
26. Kosteljanetz 1979 Kosteljanetz M, Christiansen J, Dam AM, Hansen BS, Pedersen H, Dam M. Carabamazepine vs phenytoin. A controlled clinical trial in focal motor and generalized epilepsy. Archives of Neurology 1979;36(1):22–4.
27. Kuzuya 1993 Kuzuya T, Hasegawa T, Shimizu K, Nabeshima T. Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1993;31(2): 61–5.
28. Rajotte 1967 Rajotte P, Jilek W, Jilek L, Perales A, Giard N, Bordeleau J, et al. The anti-epileptic and psychotropic properties of carbamazepine (Tegretol) [Proprietes antiepileptiques et psychotropes de la carbamazepine (Tegretol)]. L’Union Medicale du Canada 1967;96(10):1200–6.
29. Rysz 1994 Rysz A. Effect of monotherapy with phenytoin or carbamazepine on somatosensory evoked potentials in patients with newly diagnosed epilepsy. Polski Tygodnik Lekarski 1994;49(4-5):79–81.
30. Sabers 1995 Sabers A, Moller A, Dam M, Smed A, Arlien-Soborg P, Buchman J, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurologica Scandinavica 1995;92(1):19–27.
31. Shakir 1980 Shakir RA. Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants. The place of sodium valproate in the treatment of epilepsy. Royal Society of Medicine International Congress and Symposium No. 30. London: Academic Press Inc (London) Ltd and the Royal Society of Medicine, 1980:7–16.
32. Shorvon 1978 Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH. One drug for epilepsy. British Medical Journal 1978;1 (6111):474–6.
33. ∗ Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelboe J. A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy. Epilepsia 1976;17(2):169–76.
34. Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelboe J. A double blind study of carbamazepine and diphenylhydantoin in temporal lobe epilepsy. Acta Neurologica Scandinavica Supplementum 1975;60:39–42.
35. Troupin A, Ojemann LM, Halpern L, Dodrill C, Wilkus R, Friel P, et al. Carbamazepine: a double blind comparison with phenytoin. Neurology 1977;27(6):511–9.
36. Troupin 1975 Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977;27(11):1023–8.
37. Wilkus RJ, Dodrill CB, Troupin AS. Carbamazepine and the electroencephalogram of epileptics: a double blind study in comparison to phenytoin. Epilepsia 1978;19(3):283–91.
38. Troupin AS, Green JR, Halpern LM. Carbamazepine (Tegretol) as an anticonvulsant. A controlled double-blind comparison with diphenylhydantoin (Dilantin). Acta Neurologica Scandinavica Supplement 1975;60:13–26.
39. Zeng 2010 Zeng K, Wang X, Xi Z, Yan Y. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clinical Neurology and Neurosurgery 2010;112(4):291–5.
40. Annegers 1999 Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40(4):502–6.
41. Bromley 2014 Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews 2014, Issue 10. DOI: 10.1002/14651858.CD010236.pub2
42. Carl 1992 Carl GF, Smith ML. Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin. Epilepsia 1992;33(2):372–5.
43. Cockerell 1995 Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968): 140–4.
44. Commission 1981 Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22(4):489–501.
45. Commission 1989 Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389–99.
46. Gladstone 1992 Gladstone DJ, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology 1992;6(3):257–61.
47. Granger 1995 Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, et al. Modulation of the gamma aminobutyricacid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology 1995;47(6):1189–96.
48. Gruber 1962 Gruber CM, Brock JT, Dyken MD. Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, dipheylhydantoin, ethotoin, metharbital, and methylphenylhydantion in motor seizures. Clinical Pharmacology and Therapeutics 1962;3:23–8.
49. Hauser 1993 Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935-1984. Epilepsia 1993;34(3):453–68.
50. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327 (7414):557–60.
51. Higgins 2017 Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor (s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/ handbook. Cochrane.
52. Hirtz 2007 Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the ”common“ neurologic disorders?. Neurology 2007;68(5): 326–37.
53. ILAE 1998 ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39(7): 799–803.
54. ILAE 2006 Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: Evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094–120.
55. Jones 1996 Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313(7048):36–9.
56. Juul-Jenson 1983 Juul-Jenson P, Foldspang A. Natural history of epileptic seizures. Epilepsia 1983;24(3):297–312.
57. Kirkham 2010 Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
58. Kwan 2000 Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine 2000;342(5): 314–9.
59. Lefebvre 2011 Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
60. Liporace 1994 Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994;35(5):1026–8.
61. MacDonald 2000 MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology 2000;48(6):833–41.
62. Malafosse 1994 Malfosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R. Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic. Eastleigh: John Libbey and Company, 1994.
63. Marson 2000 Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 3. DOI: 10.1002/14651858.CD001030
64. Matlow 2012 Matlow J, Koren G. Is carbamazepine safe to take during pregnancy?. Candian Family Physician 2012;58(2):163–4.
65. Meador 2008 Meador K, Reynolds M, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research 2008;81(1):1–13.
66. Moher 2009 Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ 2009; 339:b2535.
67. Morrow 2006 Morrow J, Russel A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry 2006;77(2):193–8.
68. Murray 1994 Murray CJ, Lopez AD. Global Comparative Assessments in the Health Sector. Geneva: World Health Organization, 1994.
69. Nevitt 2017a Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database of Systematic Reviews 2017, Issue 12. DOI: 10.1002/14651858.CD011412.pub3
70. Nevitt 2018a Nevitt SJ, Tudur Smith C, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 6. DOI: 10.1002/14651858.CD001031.pub4
71. Nevitt 2018b Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 8. DOI: 10.1002/14651858.CD001769.pub4
72. Nevitt 2018c Nevitt SJ, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 10. DOI: 10.1002/14651858.CD003615.pub4
73. Nevitt 2018d Nevitt SJ, Marson AG, Tudur-Smith C. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2018, Issue 10. DOI: 10.1002/14651858.CD001904.pub4
74. Nevitt 2019 Nevitt SJ, Sudell M, Tudur Smith C, Marson A. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2019, Issue 6. DOI: 10.1002/14651858.CD012065.pub3
75. Ngugi 2010 Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and lifetime epilepsy: a meta-analytic approach. Epilepsia 2010;51 (5):883–90.
76. NICE 2012 National Institute for Health and Care Excellence. Epilepsies: diagnosis and management. www.nice.org.uk/ guidance/cg137 2012 (accessed 12 May 2019).
77. Nolan 2013a Nolan SJ, Sutton L, Marson A, Tudur Smith C. Consistency of outcome and statistical reporting of time-to-event data: the impact on Cochrane Reviews and meta-analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health. Quebec City, 2013:114–5.
78. Nolan 2013b Nolan SJ, Tudur Smith C, Pulman J, Marson AG. Phenobarbitone versus phenytoin monotherapy for focal onset seizures and generalised onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2013, Issue 1. DOI: 10.1002/14651858.CD002217.pub2
79. Nulman 1997 Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics 1997;68(1):18–24.
80. Olaffsson 2005 Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorfer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology 2005;4(10):627–34.
81. Pal 1998 Pal DK, Das T, Chaudhury G, Johnson AL, Neville BG. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351(9095):19–23.
82. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival end-points. Statistics in Medicine 1998;17(24): 2815–34.
83. Ragsdale 1991 Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage dependent inhibition of type hA Na channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Molecular Pharmacology 1991;40:756–65.
84. Sander 1996 Sander JW, Shorvon SD. Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61 (5):433–43.
85. Sander 2004 Sander JW. The use of anti-epileptic drugs-Principles and practice. Epilepsia 2004;45(6):28–34.
86. Scheffer 2017 Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–21.
87. Scheinfeld N. Phenytoin in cutaneous medicine: Its uses, mechanisms and side effects. Dermatology Online Journal 2003;9(3):6.
88. Shields 1983 Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33(11):1487–9.
89. Snead 1985 Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine 1985; 313(15):916–21.
90. Stata 2015 [Computer program] StataCorp. Stata Statistical Software: Release 14. CollegeStation, TX: StataCorp LP, 2015.
91. Tennis 1997 Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49(2): 542–6.
92. Tudur Smith 2007 Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007;5(8):34.
93. Wallace 1997 Wallace H, Shorvon SD, Hopkins A, O’Donoghue M. National Society of Epilepsy Guidelines. London: Royal College of Physicians, 1997.
94. Weston 2016 Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews 2016, Issue 11. DOI: 10.1002/14651858.CD010224.pub2
95. Wilder 1995 Wilder BJ. Phenytoin: clinical use. Antiepileptic Drugs. 4th Edition. New York: Raven Press, 1995:339–44.
96. Williamson 2000 Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick DW. Individual patient data meta-analysis of randomized antiepileptic drug monotherapy trials. Journal of Evaluation in Clinical Practice 2000;6(2):205–14.
97. Williamson 2002 Williamson PR, Tudur Smith C, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(11):3357–51.
98. Willow 1985 Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage sensitive sodium channels in neuroblastoma cells. Molecular Pharmacology 1985;27(5): 549–58.
99. Nevitt 2017b Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2017, Issue 2. DOI: 10.1002/14651858.CD001911.pub3
100. Nolan 2015 Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2015, Issue 8. DOI: 10.1002/14651858.CD001911.pub2
101. Tudur Smith 2002 Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2002, Issue 2. DOI: 10.1002/14651858.CD001911
102. Tudur Smith 2010 Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2010, Issue 3. DOI: 10.1002/14651858.CD001911
103. Wilson 2000 Wilson HE, Marson AG, Williamson PR, Lopes-Lima JM, Hutton JL, Chadwick DW. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 1. DOI: 10.1002/14651858.CD001911